Small molecule drug discovery for Huntington's Disease

Area of Science:

• Neuroscience
• Genetics
• Pharmacology

Background:

• Huntington's Disease (HD) is a rare neurodegenerative disorder.
• It stems from a mutation in the huntingtin gene, leading to expanded polyglutamine (polyQ) repeats.
• Current knowledge of validated HD targets is limited, hindering traditional drug discovery.

Purpose of the Study:

• To explore alternative drug discovery strategies for Huntington's Disease.
• To evaluate the utility of phenotypic assays in identifying therapeutic candidates.
• To understand how discovery strategies impact clinical trial translation.

Main Methods:

• Review of current and emerging drug discovery approaches for HD.
• Analysis of strategies focusing on inhibiting polyQ huntingtin aggregation.
• Assessment of phenotypic assays for identifying disease-modifying molecules.

Main Results:

• Traditional target-based drug discovery is limited for HD due to immature target knowledge.
• Early strategies focused on inhibiting polyQ huntingtin aggregation.
• Recent phenotypic assays have identified molecules reversing pathogenic HD mechanisms.

Conclusions:

• Novel drug discovery strategies are essential for Huntington's Disease.
• Phenotypic screening offers a viable alternative to target-based approaches for HD.
• Effective discovery strategies are crucial for advancing HD drug candidates to clinical trials.